Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells

[1] H.M. Blau, G.Q. Daley, Stem cells in the treatment of disease, N. Engl. J. Med.

380 (18) (2019) 1748e1760. May 2.

[2] J. Deinsberger, D. Reisinger, B. Weber, Global trends in clinical trials involving

pluripotent stem cells: a systematic multi-database analysis, Npj Regen Med 5

(1) (2020) 1e13. Sep 11.

[3] C. Flahou, T. Morishima, H. Takizawa, N. Sugimoto, Fit-for-all iPSC-derived cell

therapies and their evaluation in humanized mice with NK cell immunity

[Internet], Front. Immunol. (2021) [cited 2021 Apr 5];12. Available from:

https://www.frontiersin.org/articles/10.3389/fimmu.2021.662360/full?&utm_

source¼Email_to_authors_&utm_medium¼Email&utm_content¼T1_11.5e1_

author&utm_campaign¼Email_publication&field¼&journalName¼Frontiers_

in_Immunology&id¼662360.

[4] J. Harding, K. Vintersten-Nagy, A. Nagy, Universal stem cells: making the

unsafe safe, Cell Stem Cell 27 (2) (2020) 198e199. Aug.

[5] L. Riolobos, R.K. Hirata, C.J. Turtle, P.R. Wang, G.G. Gornalusse, M. Zavajlevski,

et al., HLA engineering of human pluripotent stem cells, Mol. Ther. 21 (6)

(2013) 1232e1241. Jun.

[6] L.L. Lanier, Up on the tightrope: natural killer cell activation and inhibition,

Nat. Immunol. 9 (5) (2008) 495e502. May.

[7] E.O. Long, Negative signaling by inhibitory receptors: the NK cell paradigm,

Immunol. Rev. 224 (2008) 70e84, août.

[8] E. Vivier, J.P.D. Santo, A. Moretta, M.D. Cooper, Natural killer cells, Curr. Top.

Microbiol. Immunol. (2016).

[9] H. Xu, B. Wang, M. Ono, A. Kagita, K. Fujii, N. Sasakawa, et al., Targeted

disruption of HLA genes via CRISPR-cas9 generates iPSCs with enhanced immune compatibility, Cell Stem Cell 24 (4) (2019) 566e578.e7. Apr.

[10] D. Suzuki, C. Flahou, N. Yoshikawa, I. Stirblyte, Y. Hayashi, A. Sawaguchi, et al.,

iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and

natural killer cell immunity, Stem Cell Rep. 14 (1) (2020) 49e59. Jan 14.

[11] Y. Saito, J.M. Ellegast, A. Rafiei, Y. Song, D. Kull, M. Heikenwalder, et al., Peripheral blood CD34þ cells efficiently engraft human cytokine knock-in mice,

Blood (2016).

[12] Q. Chen, M. Khoury, J. Chen, Expression of human cytokines dramatically

improves reconstitution of specific human-blood lineage cells in humanized

mice, Proc. Natl. Acad. Sci. U. S. A. 106 (51) (2009) 21783e21788. Dec 22.

[13] N.D. Huntington, N. Legrand, N.L. Alves, B. Jaron, K. Weijer, A. Plet, et al., IL-15

trans-presentation promotes human NK cell development and differentiation

in vivo, J. Exp. Med. 206 (1) (2009) 25e34. Jan 16.

[14] E. Billerbeck, W.T. Barry, K. Mu, M. Dorner, C.M. Rice, A. Ploss, Development of

human CD4þFoxP3þ regulatory T cells in human stem cell factor-,

granulocyte-macrophage colony-stimulating factor-, and interleukin-3expressing NOD-SCID IL2Rg(null) humanized mice, Blood 117 (11) (2011)

3076e3086. Mar 17.

[15] F.E. Nicolini, J.D. Cashman, D.E. Hogge, R.K. Humphries, C.J. Eaves, NOD/SCID

mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem

cell regeneration, Leukemia 18 (2) (2004) 341e347. Feb.

83

...